Biotech News

Biote Reports Third Quarter 2026 Financial Results

biote Corp (BTMD)biote CorpEarnings

Company maintains 2026 financial outlook Third Quarter 2026 Financial Summary Revenue of $43.3 million Gross profit margin of 67.7% Net income of $0.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.01 Adjusted EBITDA 1 of $5.1 million and Adjusted EBITDA

Related news

biote Corp

Hormone Optimization Biote operates a practitioner-led platform focused on hormone optimization and healthy aging. Its principal offering uses bioidentical hormone pellets implanted during office-based procedures. Practitioner Network The company trains and certifies medical practitioners, supplies procedure products and supports clinics...

Recent company news

Stock data

Close
0.84 USD
Market cap
65.21M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States